and major depressive disorder (MDD),” said Rob Barrow, Chief Executive Officer of MindMed. “Gregg’s deep expertise in leading the regulatory approvals of transformative psychiatric drugs—demonstrated ...

de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

Cybin launches Phase 3 trials for CYB003, aiming to offer lasting relief for Major Depressive Disorder. Backed by promising ...

Vancouver, British Columbia--(Newsfile Corp. - November 12, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or ...

Learn more about how an anesthetic traditionally used for surgical procedures may help depression and what to expect during ...

The understanding and treatment of psychiatric disorders present unique challenges due to these ... These systems are characterised by non-linearity, feedback loops, emergence, and multi-level ...

Mental health treatment ... with depression. No Medication Required: Unlike traditional treatments, TMS does not require ...

Global Central Nervous System Therapeutics Market is valued at approximately USD 143.95 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.5% over the forecast period ...

MindMed is poised for significant developments with MM-120 in upcoming trials. Discover why monitoring MNMD stock is ...

A subset of individuals with major depressive disorder (MDD) have a high burden of cardiovascular risk factors and cerebral small‐vessel disease, implicating vascular disease in the development of ...

Bipolar disorder is a long-term mood disorder characterized by major fluctuations in ... and then go over treatment options and coping strategies. Bipolar I is thought to be the most common ...